Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
update
/
details

SkylineDx Presents Breakthrough Data from Largest Melanoma Genomic Assay Trial at SMR Annual Meeting

NextEdge Admin

15 Oct 2024

2 min 50 sec

SkylineDx, a molecular diagnostics company focused on oncology, announced new results from the MERLIN_001 trial, the largest US multi-center study assessing the performance of a melanoma genomic assay. The first findings were shared in a late-breaking plenary session at the Society for Melanoma Research (SMR) Annual Meeting in New Orleans.

Led by Dr. Vernon Sondak (Moffitt Cancer Center), Dr. Terry Hieken (Mayo Clinic), and Dr. Michael Egger (UofL Health Brown Cancer Center), the trial involved 1,686 melanoma patients (T1-T3) across nine academic sites. It validated the predictive accuracy of the CP-GEP (Clinical-Pathologic and Gene Expression Profile) Merlin test in determining sentinel lymph node biopsy (SLNB) status for high-risk melanoma patients. SLNB is a standard staging procedure, but over 80% of biopsies reveal no metastasis, leading to unnecessary surgeries. The Merlin test offers a non-invasive solution by more accurately identifying low-risk patients, helping reduce unnecessary SLNBs and complications.

The trial showed that the Merlin test classified 37% of patients as Low-Risk, with only 7.1% having positive SLNs, yielding a 92.9% negative predictive value (NPV). High-Risk patients had a 23.8% SLN positivity rate, indicating the test’s ability to effectively stratify patients. Among T1 melanoma patients, 67% were classified as Low-Risk, with only 4.8% showing SLN metastasis.

The Merlin test integrates clinicopathologic factors like age and Breslow thickness with an 8-gene expression profile. It aligns with NCCN guidelines, guiding surgeons toward more precise, individualized care and reducing invasive procedures when appropriate. Commercially available in the US and Europe, it is marketed by Tempus as the Tempus Merlin test and by Quest Diagnostics as MelaNodal Predict™.

SkylineDx, based in Rotterdam and San Diego, focuses on transforming gene expression research into clinical diagnostics, improving patient outcomes through personalized care.